

REFERENCE TABLE
AMENDING AND SUPPLEMENTING THE CHARTER OF DHG PHARMA
AT THE GENERAL MEETING OF SHAREHOLDERS IN 2020

1. Reference guides

The underlined texts: the amendments and supplements.

~~The strikethrough texts: contents proposed to remove.~~

2. Reference contents

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>INTRODUCTION This Charter has been approved in accordance with Resolution No. 001/2020/DHDGD of the Annual General Meeting of Shareholders 2019, dated 29 June 2020.</p>	<p>INTRODUCTION This Charter has been approved in accordance with Resolution No. ...</p>	<p>Updating number, date of issuance of the new Resolution approved by the Annual General Meeting of Shareholders 2020.</p>
<p>Chapter I: GENERAL PROVISION</p>	<p>Chapter I: GENERAL PROVISION</p>	
<p>Article 2. Interpretation of term 1. In this Charter, the terms below are construed as follows:</p>		
	<p><u>“Voting capital” means the share that endows the holder the right to vote on the issues within the jurisdiction of the General Meeting of Shareholders;</u></p>	<p>Supplementing the content in accordance with clause 33, Article 4 of the Law on Enterprises 2020.</p>
<p>k. “The Law on Enterprises” means the Law on Enterprises No. 68/2014/QH13 passed by the National Assembly on 26 November 2014.</p>	<p>k. “The Law on Enterprises” means the Law on Enterprises No. <u>59/2020/QH14</u> passed by the National Assembly on <u>17 June 2020.</u></p>	<p>The Law on Enterprises No. 68/2014/QH13 was expired. Amending the content in accordance with the Law on Enterprises No. 59/2020/QH14 (replacing the Law on Enterprises No. 68/2014/QH13).</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
n. "Enterprise Executives" are the General Director, Deputy General Director, Chief Accountant, Functional Directors, and other positions within the appointed competence of the Board of Directors.	n. "Enterprise Executives" are General Director, <u>Chief Operating Officer</u> , Deputy General Director(s), Chief Accountant, Functional Director(s), and other positions within the appointing authority of the Board of Directors.	Adding the title "Chief Operating Officer" according to the reality and The Company's current organizational structure.
o. "Related person" means any individual or organization that has a direct or indirect relationship with DHG PHARMA in the cases prescribed by Clause 17, Article 4 of the Law on Enterprises and Clause 34 Article 6 of the Law on Securities.	o. "Related person" means any individual or organization that has a direct or indirect relationship with DHG PHARMA in the cases prescribed at clause <u>23</u> , Article <u>4</u> of the Law on Enterprises and clause <u>46</u> , Article <u>4</u> of the Law on Securities.	Revising/ Updating the references in accordance with the Law on Enterprises 2020 and the Law on Securities 2019.
	<u>"Relatives" of a person include the spouse, biological parents, adoptive parents, parents-in-laws, biological children, adopted children, children-in-law, biological siblings, siblings-in-law and biological siblings of the spouse.</u>	Adding the content according to clause 22, Article 4 of the Law on Enterprises 2020.
s. "Independent Board of Directors' members" are the members of the Board of Directors that satisfy the following standards and conditions: (i) Not being a current employee of DHG PHARMA or its subsidiaries; Not being a person that used to work for DHG PHARMA or its subsidiaries over the previous three (03) consecutive years;	s. "Independent board members" are the members of the Board of Directors that satisfy the following standards and conditions: (i) Not being a current employee of DHG PHARMA, its <u>parents company</u> or its subsidiaries; Not being a person that used to work for DHG PHARMA, <u>its parents company</u> or its subsidiaries over the previous three (03) consecutive years;	Adding/ Revising the content in accordance with point a, clause 2, Article 155 of the Law on Enterprises 2020.
(iii) Not having a spouse, birth parents or sibling being a major shareholder of DHG PHARMA; being an Enterprise Executive of	(iii) Not having his/her <u>spouse, biological parents, adoptive parents, biological children, adoptive children or biological siblings</u> being a major shareholder of DHG	Adding/ Revising the content in accordance with point c, clause 2, Article 155 of the Law on Enterprises 2020.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
DHG PHARMA or DHG PHARMA's subsidiaries;	PHARMA; being an Enterprise Executive of DHG PHARMA or DHG PHARMA's subsidiaries;	
(v) Not ever holding the position of members of the Board of Directors, the Board of Supervisory of DHG PHARMA for at least previous five (05) consecutive years.	(v) Not ever holding the position of members of the Board of Directors, the Board of Supervisory of the Company for at least previous five (05) consecutive years, <u>unless being appointed continuously for 02 consecutive terms.</u>	Adding/ Revising the content in accordance with point dd, clause 2, Article 155 of the Law on Enterprises 2020.
t. Audit Committee is an Internal Audit Board under the Board of Directors in accordance with point b, clause 1, Article 134 of the Law on Enterprises.	t. Audit Committee is a specialized body under the Board of Directors in accordance with <u>point b, clause 1, Article 137, and clause 1 Article 161</u> of the Law on Enterprises.	Revising the Vietnamese name of Audit Committee to unify the names of Committees under the Board of Directors. Revising/ Updating the reference in accordance with the Law on Enterprises 2020.
Article 8. Seal 1. DHG PHARMA has one (01) seal, and this seal is the property of DHG PHARMA. The Board of Directors decides the form, number, and contents of the official seal of DHG PHARMA and the official seal of DHG PHARMA's subordinate units.	Article 8. Seal 1. DHG PHARMA has one (01) seal, and this seal is the property of DHG PHARMA. The Board of Directors decides the form, number, and contents of the official seal of DHG PHARMA and the official seal of DHG PHARMA's subordinate units. <u>In case of necessity to serve production and business activities, the Board of Directors can register additional seals in the form of digital signatures in accordance with the provisions of law on electronic transactions.</u>	Adding/ Revising the content in accordance with Article 43 of the Law on Enterprises 2020 and Article 58 of the Model Charter under Circular 116/2020/TT-BTC.
	<u>3. The Board of Directors and General Director use and manage the seal in accordance with the applicable law and the regulation on seal management issued by the Board of Directors. The Company uses the seal in transactions as prescribed by law.</u>	Adding/ Revising the content in accordance with Article 43 of the Law on Enterprises 2020 and Article 58 of the Model Charter under Circular 116/2020/TT-BTC.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
Chapter II: CHARTER CAPITAL, SHARES AND FOUNDING SHAREHOLDERS	Chapter II: CHARTER CAPITAL, SHARES AND FOUNDING SHAREHOLDERS	
<p>Article 10. Share certificates</p> <p>2. Shares are certificates issued by the company, book entries or electronic data certifying ownership of one or a number of shares of DHG PHARMA. Shares must contain all contents as stipulated in Clause 1, Article 120 of the Law on Enterprises.</p>	<p>Article 10. Share certificates</p> <p>2. Shares are certificate issued by the Company, book entries or electronic certifying the ownership of one or a number of shares of DHG PHARMA. Shares shall contain all information as stipulated in <u>clause 1, Article 121</u> of the Law on Enterprises.</p>	Revising/ Updating the reference in accordance with the Law on Enterprises 2020.
<p>Article 13. Reclamation of shares</p> <p>4. The reclaimed shares shall become assets and are considered as the shares offered for sale of DHG PHARMA as stipulated in clause 3, Article 111 of the Law on Enterprises. The Board of Directors may directly execute or authorize the sale, redistribution or settlement for persons whose own shares reclaimed or other subjects under the conditions and ways which the Board of Directors deems appropriate.</p>	<p>Article 13. Reclamation of shares</p> <p>4. The reclaimed shares shall become assets and are considered as the shares offered for sale of DHG PHARMA as stipulated in <u>clause 3, Article 112</u> of the Law on Enterprises. The Board of Directors may directly execute or authorize the sale, redistribution or settlement for persons whose own shares reclaimed or other subjects under the conditions and ways which the Board of Directors deems appropriate.</p>	Revising/ Updating the reference in accordance with the Law on Enterprises 2020.
Chapter III: ORGANIZATIONAL STRUCTURE, MANAGEMENT, AND CONTROL	Chapter III: ORGANIZATIONAL STRUCTURE, MANAGEMENT, AND CONTROL	
<p>Article 14. Organizational structure, management, and control</p> <p>The organizational structure, management, governance and control of DHG PHARMA include:</p>	<p>Article 14. Organizational structure, management, and control</p> <p>The organizational structure, management, and control of DHG PHARMA include:</p> <p>1. The General Meeting of Shareholders;</p>	Adding/ Revising the content according to point b, clause 1, Article 137 of the Law on Enterprises 2020; Article 11 of the Model Charter under Circular 116/2020/TT-BTC and

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>1. The General Meeting of Shareholders; 2. The Board of Directors; 3. Audit Committee under the Board of Directors (hereinafter referred to the Audit Committee); 4. The General Director.</p>	<p>2. Boards of Directors, <u>Audit Committee under the Board of Directors.</u> 3. General Director.</p>	<p>Article 282 of Decree 155/2020/ND-CP.</p>
<p>Section A: SHAREHOLDERS AND THE GENERAL MEETING OF SHAREHOLDERS</p>	<p>Section A: SHAREHOLDERS AND THE GENERAL MEETING OF SHAREHOLDERS</p>	
<p>Article 15. Rights of shareholders c. Shareholders have the right to protect their legal rights. In case the decision of the General Meeting of Shareholders violates the law or the Charter, the Board of Directors' decisions in contrary to the provisions of law or the Charter causing damage to DHG PHARMA, shareholders have the right to propose the cancellation or suspension of such decisions in accordance with the Law on Enterprises;</p>	<p>Article 15. Rights of shareholders c. Shareholders are entitle to protect their legal rights <u>and to request for suspension, cancellation of resolutions and decisions of the General Meeting of Shareholders and the Board of Directors when (i) The resolution of the General Meeting of Shareholders violates provisions of law. (ii) or the Charter (iii) or the orders, procedures for convening and making decisions of the General Meeting of Shareholders seriously violate the provisions of the Law on Enterprises and the Company's Charter (iv) and the content of the resolution violates regulations of law or the Company's Charter.</u></p>	<p>Adding/ Revising the content according to Article 115 of the Law on Enterprises 2020 and point I, clause 1, Article 12 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>1. To request DHG PHARMA to repurchase shares in the cases stipulated in Article 129 of the Law on Enterprises;</p>	<p>1. To request DHG PHARMA to repurchase shares in the cases stipulated in <u>Article 132</u> of the Law on Enterprises;</p>	<p>Revising/ Updating the reference in accordance with the Law on Enterprises 2020.</p>
<p>3. A shareholder or a group of shareholders holding five percent (5%) or more of the total number of ordinary shares for at least six (06)</p>	<p>3. A shareholder or a group of shareholders holding five percent (5%) or more of the total number of ordinary shares shall have the following rights:</p>	<p>Adding/ Revising the content according to clause 2, Article 115 of the Law on Enterprises 2020 and</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
consecutive months or more shall have the following rights:		clause 2, Article 12 of the Model Charter under Circular 116/2020/TT-BTC.
a. To nominate members to the Board of Directors according to the respective provisions of Clause 1 of Article 33 of this Charter.		Moving and expanding at clause 6 of this Article.
b. To request the Board of Directors to convene the meeting of the General Meeting of Shareholders in accordance with Article 114 and Article 136 of the Law on Enterprises. The request must be made in writing, accompanied by the required documents and evidence of the violations of the Board of Directors, the extent of the violations or the decisions beyond its competence.	b. To request the Board of Directors to convene the General Meeting of Shareholders in accordance with <u>clause 3 Article 115 and Article 140</u> of the Law on Enterprises and <u>clause 4 of this Article.</u>	Revising/ Updating the references in accordance with the Law on Enterprises 2020. Moving the “the request must be made in writing ... competence” content to clause 5 of this Article.
	d. <u>Examine, extract the minutes, resolutions and decisions of the Board of Directors, interim and annual financial statements, reports of the Audit Committee, contracts and transactions subject to approval by the Board of Directors and other documents, except documents relevant to the Company’s trade secrets;</u>	Adding the content in accordance with clause 2 Article 12 of the Model Charter under Circular 116/2020/TT-BTC.
	<u>Propose inclusion of issues in the agenda of the General Meeting of Shareholders. The proposal must be made in writing and sent to the Company at least 03 working days before the opening date. The proposal shall specify the shareholder’s name, quantity of each</u>	Adding the content in accordance with clause 2 Article 12 of the Model Charter under Circular 116/2020/TT-BTC.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
	<u>type of shares being held by the shareholder and the proposed issues;</u>	
	<u>4. A shareholder or group of shareholders defined in clause 3 of this Article has the right to request convening the General Meeting of Shareholders in the following cases:</u>	Adding according to clause 3, Article 115 of the Law on Enterprise 2020.
	<u>a. The Board of Directors seriously violates the rights of shareholders, the obligations of the manager or makes a decision beyond its assigned authority;</u>	
	<u>b. Other cases as stipulated in the Company's Charter.</u>	
	<u>5. The request to convene a meeting of the General Meeting of Shareholders specified in clause 4 of this Article must be made in writing and contain full names, mailing addresses, nationalities, legal document numbers of shareholders that are individuals; names, business code or legal document numbers, headquarters addresses of shareholders that are organizations; quantities of shares and time of shares registration of each shareholder, total quantity of shares of the group and their holdings in the company; the reasons for convening the General Meeting of Shareholder. The request shall be enclosed with documentary evidence of the violations committed by the Board of Directors, seriousness of the violation or the decision issued ultra vires.</u>	Adding the content according to clause 4, Article 115 of the Law on Enterprises 2020 and point dd, clause 2, Article 12 of the Model Charter under Circular 116/2020/TT-BTC.
	<u>6. A shareholder or a group of shareholders that holds at least 5% of total ordinary shares is entitled to nominate candidates to the Board of Directors. The</u>	Adding the content according to clause 5, Article 115 of the Law on Enterprises 2020 and clause 3,

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
	<p><u>nomination to the Board of Directors is carried out as follows:</u></p> <p><u>a. Ordinary shareholders who meet in group to nominate candidates to the Board of Directors must inform the participating shareholders before the opening of the General Meeting of Shareholders;</u></p> <p><u>b. Depending on the quantity of members of the Board of Directors, a shareholder or a group of shareholders prescribed at clause 6 of this Article may nominate one or several candidates in accordance with clause 1 Article 33 of this Charter.</u></p> <p><u>In case the number of nominated candidates is smaller than the maximum permissible number of candidates specified in the decision of the General Meeting of Shareholders, the remaining candidates shall be nominated by Board of Directors and other shareholders in accordance with clause 1 Article 33 of this Charter.</u></p>	<p>Article 12 of the Model Charter under Circular 116/2020/TT-BTC.</p> <p>Revising the ownership to 5% to be consistent with clause 1 Article 33 of this Charter</p>
	<p><u>7. Other rights as prescribed by the Law on Enterprises and this Charter.</u></p>	<p>Adding the content according to clause 6, Article 115 of the Law on Enterprises 2020.</p>
<p>Article 16. Obligations of shareholders</p> <p>1. Shareholders have the following obligations:</p>	<p>Article 16. Obligations of shareholders</p> <p>1. Shareholders have the following obligations:</p>	
<p>a. Not to withdraw the capital contributed as ordinary shares from DHG PHARMA in any form, except in the case of DHG PHARMA or others repurchase the shares. If a shareholder withdraws a part or all of the</p>	<p>a. Not to withdraw the capital contributed as ordinary shares from DHG PHARMA in any form unless the shares are re-purchased by DHG PHARMA or other persons. If the shareholder withdraws all or part of the share capital against regulations of this point, members</p>	<p>Adding according to clause 2, Article 119 of the Law on Enterprises and clause 2, Article 13 of the Model Charter under Circular 116/2020/TT-BTC.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>contributed share capital in contravention of this point, members of the Board of Directors and the legal representative of DHG PHARMA shall be jointly liable for the debts and other asset obligations of DHG PHARMA within the value of equity have been withdrawn.</p>	<p>of the Board of Directors and the legal representative of DHG PHARMA shall be jointly liable for DHG PHARMA's liabilities and other asset obligations which are equal to the value of the shares withdrawn and <u>damages</u> caused by this action.</p>	
<p>c. To pay for shares according to the number of shares which the shareholder has registered to subscribe in accordance with the regulations;</p>	<p>c. To pay <u>fully and on time</u> the committed shares to <u>purchase</u>.</p>	<p>Adding/ Revising the content according to clause 1, Article 119 of the Law on Enterprises 2020 and clause 1, Article 13 of the Model Charter under Circular 116/2020/TT-BTC.</p>
	<p><u>To protect the confidentiality of information provided by the Company in accordance with the Company's Charter and the law; only use the provided information to perform and protect their lawful rights and interests; it is prohibited to spread or share information provided by the Company to any other organization or individual.</u></p>	<p>Adding the content according to clause 5, Article 119 of the Law on Enterprises 2020 and clause 5, Article 13 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>g. To attend the meeting of the General Meeting of Shareholders and exercise the voting right in the following forms: (iii) To attend and vote via online meetings, electronic voting or other electronic forms;</p>	<p>g. To attend the General Meeting of Shareholders and exercise the voting right in the following forms: (iii) To attend and vote via online meetings, electronic voting or other electronic forms <u>in accordance with the voting rule and the agenda of the General Meeting of Shareholders;</u></p>	<p>Adding the content according to point c, clause 6, Article 13 of the Model Charter under Circular No. 116/2020/TT-BTC.</p>
<p>2. The organizations and individuals who become major shareholders of DHG PHARMA, apart from the obligations prescribed by Clause 1 this</p>	<p>2. The organizations and individuals who become <u>or no longer become</u> major shareholders of DHG PHARMA, apart from the obligations prescribed at clause 1 of this Article and disclose information in</p>	<p>Adding the content in accordance with clause 1 Article 31 in Circular 96/2020/TT-BTC dated 16 November 2020</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>Article and disclose information in accordance with regulations of law, must also fulfill obligations to report to DHG PHARMA, the State Securities Commission and the Stock Exchange where stocks of DHG PHARMA are listed within seven (07) days after they become majority shareholders. A report on a majority shareholder's ownership covers the following contents:</p> <p>a. The name, address and business lines in case of a major shareholder being an organization; Full name, age, nationality, residence, and profession in case of a major shareholder being an individual;</p> <p>b. The number and percentage of shares owned by organizations or individual or jointly with other organizations or individuals on the total number of outstanding shares.</p>	<p>accordance with regulations of law, must also fulfill obligations to report to DHG PHARMA, the State Securities Commission and the Stock Exchange <u>within five (05) working days after they become or no longer become majority shareholders in accordance with the sample prescribed at Appendix VII of Circular 96/2020/TT-BTC dated 16 November 2020.</u></p>	
<p>3. If there is an important change in the information in the report stipulated in Clause 2 of this Article, or if there is a change in the number of shares owned in excess of one percent (1%) of the number of shares of the same class currently in circulation, then within seven (07) days from the date of such change, the major shareholder must submit an amendment or supplement report to DHG PHARMA,</p>	<p>3. If there is an important change in the information in the report stipulated in clause 2 of this Article, or if there is a change in the number of shares owned in excess of one percent (1%) of the number of shares of the same class currently in circulation, then within <u>five (05)</u> working days from the date of such change <u>in accordance with the samples prescribed at Appendix VIII in Circular 96/2020/TT-BTC dated 16 November 2020</u>, the major shareholder must submit an amendment or</p>	<p>Adding the content in accordance with clause 2 Article 31 in Circular 96/2020/TT-BTC dated 16 November 2020</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
the State Securities Commission and the Stock Exchange where the shares are listed.	supplement report to DHG PHARMA, the State Securities Commission and the Stock Exchange where the shares are listed.	
<p>Article 17. The General Meeting of Shareholders</p> <p>1. The General Meeting of Shareholders shall be the highest competent authority of DHG PHARMA. The Annual General Meeting of Shareholders shall be organized once every year and must be held within four (04) months from the end of a fiscal year. At the request of the Board of Directors, this period of time may be extended if approved by the Authority issuing the Business Registration Certificate, but not exceeding six (06) months from the end of the fiscal year.</p>	<p>Article 17. The General Meeting of Shareholders</p> <p>1. The General Meeting of Shareholders shall be the highest competent authority of DHG PHARMA. The Annual General Meeting of Shareholders shall be organized once every year and must be held within four (04) months from the end of a fiscal year. The Board of Directors decides on the extension of the Annual General Meeting of Shareholders, but not exceeding six (06) months from the end of the fiscal year.</p> <p><u>In addition to the annual meeting, the General Meeting of Shareholders may hold extraordinary meetings. The venue of the General Meeting of Shareholders is determined to be the place where the chairperson attends the meeting and must be in the territory of Vietnam.</u></p>	Adding the content according to clause 1, Article 14 of the Model Charter under Circular No. 116/2020/TT-BTC and clause 1, clause 2 Article 139 of the Law on Enterprises 2020.
2. The Board of Directors convenes the meeting of Annual General Meeting of Shareholders and selects the appropriate venue. The Annual General Meeting of Shareholders shall make decisions on issues in accordance with the law and this Charter, especially the annual financial statements and estimation for the next fiscal year. In cases where the audited financial statements of DHG PHARMA have significant exceptions, DHG PHARMA may invite	2. The Board of Directors convenes the Annual General Meeting of Shareholders and selects the appropriate venue. The Annual General Meeting of Shareholders shall make decisions on issues in accordance with the law and this Charter, especially the annual financial statements and estimation for the next fiscal year. In cases where the audited financial statements of DHG PHARMA have material exceptions, <u>opposite opinions or refusal from the auditor</u> , the Company must invite representative(s) of <u>the accredited audit organization that audited the</u>	Adding the content according to clause 2, Article 14 of the Model Charter under Circular No. 116/2020/TT-BTC for clarification.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
representatives of the independent auditor to attend the meeting of the General Meeting of Shareholders in terms of giving explanation on related contents.	<u>Company's financial statements to participate in the Annual General Meeting of Shareholders. The invited representative of the audit organization has the responsibility to participate in the Annual General Meeting of Shareholders</u> in terms of giving explanation on related contents.	
c. The number of the Board of Directors' members, independent Board of Directors' members are less than the number of members required by law or the number of the Board of Directors' members are reduced by more than one-third (1/3) compared to the number of members stipulated in Clause 2 Article 32 of this Charter;	c. The <u>remaining</u> number of the Board of Directors' members, independent board members are less than <u>the minimum</u> number of members required by law or the number of the Board of Directors' members are reduced by more than one-third (1/3) compared to the number of members stipulated in clause 2 Article 32 of this Charter;	Adding the text in accordance with point b clause 1 Article 140 of the Law on Enterprises 2020 and point b clause 3 Article 14 of the Model Charter under Circular 116/2020/TT-BTC.
4. To convene an extraordinary meeting of the General Meeting of Shareholders	4. To convene extraordinary General Meetings of Shareholders	
b. If the Board of Directors fails to convene the meeting of the General Meeting of Shareholders in accordance with Point a, Clause 4 of this Article, then within the next thirty (30) days, a shareholder or a group of shareholders as stipulated in Point e, Clause 3 of this Article shall have the right to replace the Board of Directors to convene the meeting of the General Meeting of Shareholders. In this case, a shareholder or a group of shareholders convening the meeting of the General Meeting of Shareholders shall have the right to request	b. If the Board of Directors fails to convene the General Meeting of Shareholders in accordance with point a, clause 4 of this Article, then within the next thirty (30) days, a shareholder or a group of shareholders as stipulated in point e, clause 3 of this Article shall have the right to replace the Board of Directors to convene the General Meeting of Shareholders. In this case, the requesting shareholder or group of shareholders may request the business registration authority to supervise the <u>process of convening, conducting and decision-making of the General Meeting of Shareholders. The costs of convening and conducting the General Meeting of Shareholders shall</u>	Adding the content in accordance with clause 3, Article 140 of the Law on Enterprises 2020 and clause 4, Article 14 of the Model Charter under Circular No. 116/2020/TT-BTC for clarification.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
the Business Registration Authority to supervise the convening and conduct the meeting if necessary.	<u>be reimbursed by the Company. These costs do not include the costs incurred by the shareholders during their participation in the General Meeting of Shareholders, including accomodation and travel costs.</u>	
	<u>Procedures to hold the General Meeting of Shareholders are specified in Article 21 of this Charter.</u>	Reference is made to Article 21 of the Charter (according to clause 5, Article 140 of the Law on Enterprises 2020 and clause 2, Article 14 of the Model Charter under Circular 116/2020/TT-BTC)
<p>Article 18. Rights and duties of the General Meeting of Shareholders</p> <p>1. The Annual General Meeting of Shareholders shall be held at least once (01) a year and it is not held by way of collecting shareholders' opinions by solicitation of written consent. The Annual General Meeting of Shareholders has the right to discuss and approve:</p> <p>b. Report of the Board of Directors evaluating the status of business management in DHG PHARMA;</p>	<p>Article 18. Rights and duties of the General Meeting of Shareholders</p> <p>1. The Annual General Meeting of Shareholders shall be held at least once (01) a year and it is not held by way of collecting shareholders' opinions by solicitation of written consent. The Annual General Meeting of Shareholders has the right to discuss and approve:</p> <p>b. <u>Report of the Board of Directors on corporate and the performance of the Board of Directors and each member of the Board of Directors; independent board members are responsible for reporting at the Annual General Meeting of Shareholders as stipulated in Article 284 of the Decree No. 155/2020/ND-CP dated 31 December 2020 detailing the implementation of a number of articles of the Law on Securities.</u></p>	Adding according to point c, clause 2 Article 15 of the Model Charter under Circular 116/2020/TT-BTC and Article 284 of Decree 155/2020/ND-CP
	<u>The Company's annual business plan;</u>	Adding the content in accordance with point a, clause 3 Article 139 of the Law on Enterprises 2020.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>2. The Annual and Extraordinary General Meeting of Shareholders shall make decisions on the following issues:</p> <p>f. Total remuneration of the Board of Directors' members and reports on the Board of Directors' remuneration;</p>	<p>2. The Annual and Extraordinary General Meeting of Shareholders shall make decisions on the following issues:</p> <p><u>f. Making decisions on the budget or total remunerations, bonuses and other benefits for the Board of Directors.</u></p>	<p>Adding the content in accordance with point k, clause 2, Article 138 of the Law on Enterprises 2020 and point k, clause 1; point i, clause 2, Article 15 of the Model Charter under 116/2020/TT-BTC for clarification.</p>
<p>g. Supplement and amendment to DHG PHARMA's Charter, Regulations on internal governance;</p>	<p><u>g. Making decisions to amend and supplement the Charter of DHG PHARMA;</u> <u>Approving the internal regulation on corporate governance and the operational regulation of the Board of Directors.</u></p>	<p>Revising the texts according to point dd and l, clause 2, Article 138 of the Law on Enterprises 2020 and point dd and l clause 1, point l and t clause 2, Article 15 of the Model Charter under Circular 116/2020/TT-BTC for clarification.</p>
<p>j. Dissolution (liquidation) of DHG PHARMA and appointment of liquidators;</p>	<p>j. <u>Restructuring</u>, dissolution (liquidation) of DHG PHARMA and appointment of liquidators;</p>	<p>Adding/ Revising the texts according to point i, clause 2, Article 138 of the Law on Enterprises 2020 and point i, clause 1; point o, clause 2, Article 15 of the Model Charter under Circular 116/2020/TT-BTC for clarification.</p>
<p>k. Examine and handle violations of the Board of Directors that may cause damage to DHG PHARMA and DHG PHARMA's shareholders;</p>	<p>k. <u>Reviewing</u> and handling violations of the Board of Directors that may cause damages to DHG PHARMA and DHG PHARMA's shareholders;</p>	<p>Adding/ Revising the texts according to point h, clause 2, Article 138 of the Law on Enterprises 2020 and point h, clause 1, Article 15 of the Model Charter under Circular 116/2020/TT-BTC for clarification.</p>
<p>n. DHG PHARMA or subsidiaries of DHG PHARMA sign contracts with persons defined in Clause 1, Article 162 of the Law on Enterprise with a value of twenty percent</p>	<p>n. DHG PHARMA or subsidiaries of DHG PHARMA sign contracts with persons defined in <u>clause 1, Article 167</u> of the Law on Enterprises with a value of twenty percent (20%) or more of the total value of DHG</p>	<p>Revising/ Updating the reference in accordance with the Law on Enterprises 2020.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
(20%) or more of the total value of DHG PHARMA's assets recorded in the most recent audited financial statement;	PHARMA's assets recorded in the most recent audited financial statements;	
p. Report of the Board of Directors on governance and performance of the Board of Directors and each member of the Board of Directors, results of internal audit of the Audit Committee;	p. Report of the Board of Directors on governance and performance of the Board of Directors and each member of the Board of Directors, results of internal audit of the Audit Committee;	Revising the Vietnamese name of Audit Committee to be consistent with the change of Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/NĐ-CP.
q. Selecting an audit firm;	<u>q. Approving the list of accepted auditing firms; deciding on the selection of accepted auditing firm to audit the Company's operations, dismissing the approved auditor when deeming it necessary;</u>	Supplementing and explaining the content in accordance with point m, clause 2, Article 138 of the Law on Enterprises 2020 and point m, clause 1 and point k, clause 2, Article 15 of the Model Charter under Circular 116/2020/TT-BTC for clarification.
s. Adjustment of DHG PHARMA's organizational structure in accordance with Article 134 of the Law on Enterprises;	s. Adjustment of DHG PHARMA's organizational structure in accordance with <u>Article 137</u> of the Law on Enterprises;	Revising/ Updating the reference in accordance with the Law on Enterprises 2020.
Article 19. Authorized representatives	Article 19. Authorized representatives	
1. Shareholders who are entitled to attend the General Meeting of Shareholders in accordance with the law may directly attend or authorize their proxies to attend. In cases more than one authorized representative is appointed, the number of shares and the number of votes of each representative must be specified. Shareholders may authorize the Board of Directors or depository	1. Shareholders who are entitled to attend the General Meeting of Shareholders in accordance with the law may directly attend or authorize their proxies to attend. In cases more than one authorized representative is appointed, the number of shares and the number of votes of each representative must be specified. Shareholders may authorize the Board of Directors or depository institutions to represent them at the General Meeting of Shareholders. If the depository institutions	Revising in accordance with Clause 2, Article 16 of the Model Charter under Circular 116/2020/TT-BTC.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>institutions to represent them at the General Meeting of Shareholders. If the depository institutions are authorized by the shareholders to act as their representatives, the depository institutions shall have to publicize the contents entitled to vote. Persons authorized to attend the General Meeting of Shareholders are not allowed to re-authorize the third party to attend the meeting.</p>	<p>are authorized by the shareholders to act as their representatives, the depository institutions shall have to publicize the contents entitled to vote.</p>	
<p>2. Authorization for a proxy must be made in writing on the standard form of DHG PHARMA and must be signed in accordance with the following provisions:</p> <p>a. If an individual shareholder is a principal, the power of attorney must be signed by such shareholder and the individual/legal representative of the organization authorized to attend the meeting;</p> <p>b. If an organization shareholder is a principal, the power of attorney must be signed by the authorized representative, the legal representative of the organization shareholder, and the individual/legal representative of the organization authorized to attend the meeting;</p> <p>c. In other cases, there must be the signature of the legal representative of the shareholder and the proxy to attend the meeting;</p>	<p>2. Authorization for an individual or organization to attend the General Meeting of Shareholders in accordance with clause 1 of this Article must be made in writing. <u>The power of attorney must be made in accordance with civil laws and specify the names of the authorizer, proxy, the quantity of shares authorized, scope of authorization, term of authorization, signatures of the authorizer and the proxy.</u></p> <p>The proxy must submit his/her power of attorney when registering at the Meeting.</p> <p><u>In case of re-authorization, the meeting participant must present the original power of attorney of the shareholder or the authorized representative of organization shareholder (if it has not been registered with the Company before).</u></p>	<p>Adding and explaining the content in accordance with clause 2, Article 144 of the Law on Enterprises 2020 and clause 2, Article 16 of the Model Charter under Circular 116/2020/TT-BTC for clarification.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
Any proxy to attend the General Meeting of Shareholders must submit the power of attorney when registering for the meeting before he/she enters the meeting room.		
<p>Article 21. Convening, agenda and notice of the meeting of the General Meeting of Shareholders</p> <p>2. The person who convenes the meeting of the General Meeting of Shareholders must carry out the following duties:</p>	<p>Article 21. Convening, agenda and notice of the General Meeting of Shareholders</p> <p>2. The convener of the General Meeting of Shareholders must carry out the following duties:</p>	
	<p><u>Providing information and resolving complains related to the list of shareholders;</u></p>	<p>Adding to the content in accordance with point b, clause 5, Article 140 of the Law on Enterprises 2020.</p>
<p>a. Prepare a list of all shareholders entitled to attend the meeting of the General Meeting of Shareholders no earlier than ten (10) working days before the date of sending the notice of the meeting of the General Meeting of Shareholders;</p>	<p>a. Prepare a list of all shareholders entitled to attend the General Meeting of Shareholders <u>no later than ten</u> (10) days before the sending date of the meeting notice. <u>The Company must disclose information on the preparation of the list of shareholders entitled to attend the General Meeting of Shareholders at least 20 days prior to the record date.</u></p>	<p>Adding the texts in accordance with point a, clause 2 Article 18 of the Model Charter under Circular 116/2020/TT-BTC and clause 1 Article 141 of the Law on Enterprises 2020 for clarification.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>3. The notice of the meeting of the General Meeting of Shareholders is sent to all shareholders by a guaranteed method, and at the same time shall be published on the media means (website) of DHG PHARMA, the State Securities Committee and Stock Exchange.</p> <p>The convener of the meeting of the General Meeting of Shareholders must send the notice of meeting to all shareholders satisfying all conditions for attending and voting at the meeting at least fifteen (15) days prior to the opening day of the meeting of the General Meeting of Shareholders, (calculated from the date on which the notice is validly sent or delivered, the postal charge is paid, or the notice is put in the mailbox).</p> <p>The agenda of the meeting of the General Meeting of Shareholders and documents relating to the matters to be voted at the meeting shall be sent to the shareholders or/and published on the website of the Company. In the case where no document is attached with the notice of the meeting of the General Meeting of Shareholders, the notice inviting to the meeting must specify the website address in order to enable the shareholders to access such documents, including:</p>	<p>3. The meeting notice of the General Meeting of Shareholders is sent to all shareholders by a guaranteed method, and at the same time shall be published on the media means (website) of DHG PHARMA, the State Securities Committee and Stock Exchange.</p> <p>The convener of the General Meeting of Shareholders must send the meeting notice to all shareholders satisfying all conditions for attending and voting at the meeting at least <u>twenty first (21) days</u> prior to the opening day of the General Meeting of Shareholders, (calculated from the date on which the notice is validly sent or delivered, the postal charge is paid, or the notice is put in the mailbox). The meeting agenda of the General Meeting of Shareholders and documents relating to the matters to be voted at the meeting shall be sent to the shareholders or/and published on the website of the Company. In case where no document is attached with the meeting notice of the General Meeting of Shareholders, the meeting notice must specify the link for shareholders to access such documents, including:</p>	<p>Adding the explanation according to clause 1, Article 143 of the Law on Enterprises 2020.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
6. The person convening the meeting of the General Meeting of Shareholders shall have the right to refuse any recommendation related to Clause 5 of this Article in the following cases:	6. The convener of the General Meeting of Shareholders shall have the right to refuse any recommendation related to clause 5 of this Article in the following cases:	Deleting the texts in accordance with clause 2, Article 115 of the Law on Enterprises 2020 and point b, clause 5, Article 18 of the Model Charter under Circular 116/2020/TT-BTC for clarification.
b. At the time of the recommendation, the shareholder or group of shareholders does not own five percent (5%) or more of the ordinary shares for at least six (06) consecutive months;	b. At the time of making recommendation, the shareholder or group of shareholders does not own five percent (5%) or more of the ordinary shares.	
Article 22. Effect of resolutions of the General Meeting of Shareholders	Article 22. Effect of resolutions of the General Meeting of Shareholders	
3. Where a shareholder or group of shareholders request a court or arbitrator to cancel the resolutions of the General Meeting of Shareholders in accordance with Article 147 of the Law on Enterprises, such resolutions shall still be effective until the Court and the Arbitrator make a different decision, except for cases of application of temporary emergency measures under the decision of the competent authority.	3. When a shareholder or group of shareholders requests a court or arbitrator to cancel the resolutions of the General Meeting of Shareholders in accordance with <u>Article 151</u> of the Law on Enterprises, such resolutions shall still be effective until the Court and the Arbitrator make a different decision, except for cases of application of temporary emergency measures under the decision of the competent authority.	Revising/ Updating the reference according to the Law on Enterprises 2020.
Article 24. Procedures for conducting the meeting and voting at the meeting of the General Meeting of Shareholders	Article 24. Procedures for conducting and voting at the General Meeting of Shareholders	
5. The Chairman of the Board of Directors shall act as Chairman of the Presidium of all the meetings convened by the Board of Directors. In case the Chairman is absent or	5. The Chairperson of the Board of Directors shall chair <u>or authorize another member of the Board of Directors to chair</u> the General Meeting of Shareholders if it is convened by the Board of Directors. If the Chairperson	Revising the content in accordance with point a, clause 2, Article 146 of the Law on Enterprises 2020 and point a, clause 2, Article 20 of the

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>is temporarily unable to work, then the remaining members of the Board of Directors shall elect one of them to act as the Chairman of the Presidium of the meeting by a majority vote.</p> <p>In other cases, the person who signed the document convening the meeting of the General Meeting of Shareholders shall arrange for the meeting of the General Meeting of Shareholders to elect the Chairman of the Presidium of the meeting and the person with the highest number of votes shall act as the Chairman of the Presidium of the meeting. In the event of election of the Chairman of the Presidium, the name of the elected Chairman and the number of votes for the Chairman must be announced.</p>	<p>of the Board of Directors is absent or temporarily not able to work, other members of the Board of Directors shall elect one of them as the Chair under the majority rule.</p> <p>In other cases, the person who signed to convene the General Meeting of Shareholders controls the General Meeting of Shareholders to elect the Chairperson of the meeting and the person with the highest number of votes shall be appointed as the Chairperson of the meeting. In case of electing a Chairperson, name of the Chairperson appointed and the number of votes for this person shall be announced.</p>	<p>Model Charter under Circular 116/2020/TT-BTC.</p>
	<p><u>The Chairperson appoints one or more people to be the secretary(s) of the meeting;</u></p>	<p>Adding the content in accordance with point c, clause 2, Article 146 of the Law on Enterprises 2020 and point c, clause 2, Article 20 of the Model Charter under Circular 116/2020/TT-BTC.</p>
	<p><u>The General Meeting of Shareholders elects one or more persons to join the vote counting committee at the request of the chairperson of the meeting;</u></p>	<p>Adding the content in accordance with point d, clause 2, Article 146 of the Law on Enterprises 2020 and point d, clause 2, Article 20 of the</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
		Model Charter under Circular 116/2020/TT-BTC.
	<u>10. In case the Company applies modern technology to hold an online General Meeting of Shareholders, the Company shall ensure that shareholders are able to participate and vote electronically in accordance with Article 144 of the Law on Enterprises and clause 3 Article 273 of Decree No. 155/ND-CP dated 31 December 2020 elaborating some Articles of the Law on Securities.</u>	Adding the content in accordance with clause 10, Article 20 of the Model Charter under Circular 116/2020/TT-BTC and <u>clause 3, Article 273 of Decree 155/2020/ND-CP</u> to match the current practice.
The person convening the meeting of the General Meeting of Shareholders shall have the following rights	<u>The convener or the Chairperson of the General Meeting of Shareholders has the following rights:</u>	Adding the content in accordance with clause 7 Article 146 of the Law on Enterprises 2020 and clause 7 Article 20 of the Model Charter under Circular 116/2020/TT-BTC
<p>Article 25. Approving the decisions of the General Meeting of Shareholders</p> <p>1. The decisions of the General Meeting of Shareholders shall be adopted when it is approved by a number of shareholders with voting rights that represent fifty-one percent (51%) or more of all votes of shareholders who are present in person or by an authorized representative at the meeting of General Meeting of Shareholders for the following issues:</p> <p>g. Report of the Audit Committee on the assessment results of DHG PHARMA's operation and finance; supervisory results</p>	<p>Article 25. Approving the decisions of the General Meeting of Shareholders</p> <p>1. The decisions of the General Meeting of Shareholders shall be adopted when it is approved by a number of shareholders with voting rights that represent fifty-one percent (51%) or more of all votes of shareholders who are present in person or by an authorized representative at the General Meeting of Shareholders for the following issues:</p> <p>g. Report of the Audit Committee on the assessment results of DHG PHARMA's operation and finance; supervisory results over the members of the Board of Directors, the Board of Management and other managers; report evaluating the coordination of</p>	Revising the Vietnamese name of Audit Committee to be consistent with the change of Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
over the members of the Board of Directors, the Board of Management and other managers; report evaluating the coordination of activities between the Board of Directors, the General Director and other managers; and	activities between the Board of Directors, the General Director and other managers; and	
Article 26. Competence and procedures for collecting shareholders' opinions by solicitation of written consent to adopt the resolution of the General Meeting of Shareholders	Article 26. Competence and procedures for collecting shareholders' opinions by solicitation of written consent to adopt the resolution of the General Meeting of Shareholders	
3. Voting ballots must have the following main contents: c. Full name, permanent address, nationality, citizen identification number/ID card number/Passport or lawful identity documents if the shareholder is an individual; Name, business code or number of establishment decision, address of head office if shareholder is an organization, or full name, permanent address, nationality, citizen identification number/ID card number/Passport or lawful identity documents if the proxy of shareholder is an organization; the number of shares of each class and number of votes of the shareholder;	3. Voting ballots must have the following main contents: c. Full name, mailing address, nationality, <u>legal document number of the individual if shareholder is an individual; name, business code or legal document number of the organization, address of the headquarters if shareholder is an organization or full name, mailing address, nationality, legal document number of the organization's representative if the shareholder is an organization;</u> quantity of each type of shares and number of votes of the shareholder;	Revising the content in accordance with point c, clause 3, Article 149 of the Law on Enterprises 2020 and point c, clause 3, Article 22 of the Model Charter under Circular 116/2020/TT-BTC.
Article 27. Minutes of the meeting of the General Meeting of Shareholders	Article 27. Meeting minutes of the General Meeting of Shareholders	Adding the content in accordance with clause 1, Article 150 of the Law

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>1. The meeting of the General Meeting of Shareholders must be recorded in the minutes and may be recorded or typed and stored in other electronic forms. The minutes must be written in Vietnamese, and English version may be prepared. In addition, the minutes shall have the following main contents:</p> <p>i. Signature of the Chairman of the Presidium and Secretary.</p> <p>The minutes of the meeting of the General Meeting of Shareholders must be completed and approved before the closing of the meeting of the General Meeting of Shareholders.</p>	<p>1. The General Meeting of Shareholders must be recorded in the minutes and may be recorded or typed and archived in other electronic forms. The minutes must be written in Vietnamese, and an English version may be prepared. In addition, the minutes shall have the following main contents:</p> <p>i. <u>Full names and signatures of the Chairperson and the Secretary.</u></p> <p><u>In case the Chairperson, the Secretary refuse to sign the minutes of meeting, the minutes of meeting shall be effective if it is signed by all other members of the Board of Directors attending the meeting and fully contains the contents as prescribed in this clause. Minutes of the meeting clearly state that the Chairperson and Secretary refused to sign the meeting minutes.</u></p> <p>The minutes of meeting of the General Meeting of Shareholders shall be completed and approved before the closing of the General Meeting of Shareholders.</p> <p><u>The Chairperson and the Secretary or other persons signing the minutes of meeting shall be jointly responsible for the truthfulness and accuracy of the content of the minutes.</u></p>	<p>on Enterprises 2020 and point 1, clause 1 and clause 2, Article 23 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>Section B: THE BOARD OF DIRECTORS</p>	<p>Section B: THE BOARD OF DIRECTORS</p>	
<p>Article 29. Powers and obligations of the Board of Directors</p> <p>4. The rights and obligations of the Board of Directors shall be regulated by the law, the Charter and the internal regulations of DHG</p>	<p>Article 29. Powers and obligations of the Board of Directors</p> <p>4. The rights and obligations of the Board of Directors shall be regulated by the law, the Charter and the internal regulations of DHG PHARMA and the</p>	<p>Adding the content in accordance with point p, clause 2, Article 153 of the Law on Enterprises 2020 and point p, clause 2, Article 27 of the</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>PHARMA and the decision of the General Meeting of Shareholders. Specifically, the Board of Directors has the following powers and obligations:</p> <p>a. Rights to recommend, propose: (vi) To propose classes of stock to be issued and total number of issued stock by class;</p>	<p>decisions of the General Meeting of Shareholders. Specifically, the Board of Directors has the following powers and obligations:</p> <p>a. Rights to petition, propose: <u>(vi) To petition the restructuring, dissolution of the company; request for bankruptcy of the company;</u></p>	<p>Model Charter under Circular 116/2020/TT-BTC.</p>
<p>b. Rights to decide: (iv) Deciding on the establishment of subsidiaries, branches, and representative offices;</p>	<p>b. Rights to decide: <u>(iv) Promulgating the Financial Management Regulation, Investment Management Regulation, the Regulation on Seal Management and Utilization, and other regulations if necessary; Promulgating the Operational Regulation of the Board of Directors, the Internal Regulation on Corporate Governance after they are approved by the General Meeting of Shareholders.</u> <u>Approving the Operational Regulation of Audit Committee of DHG PHARMA, deciding on the establishment of subsidiaries, branches, representative offices and capital contribution, share purchase of other enterprises.</u></p>	<p>Adding the content in accordance with point I, clause 2, Article 153 of the Law on Enterprises 2020 and point I, q, clause 2, Article 27 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>(xi) The decision to buy back no more than ten percent (10%) of each class of issued shares. For the acquisition of shares of each type offered for sale within twelve (12) months, this must comply with the provisions of Article 130 of the Law on Enterprises and the Law on securities purchase and transfer;</p>	<p>(xi) The decision to repurchase no more than ten percent (10%) of each class of issued shares. For the acquisition of shares of each type offered for sale within twelve (12) months, this must comply with the provisions of <u>Article 133</u> of the Law on Enterprises and the applicable Law on securities purchase and transfer;</p>	<p>Revising/ Updating the reference in accordance with the Law on Enterprises 2020.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>5. The Board of Directors must report to the General Meeting of Shareholders on its performances, in particular on the supervision of the Board of Directors over Enterprise Managers, Enterprise Executives in the financial year. The Board of Directors' report on performance submitting to the General Meeting of Shareholders must include the following contents:</p>	<p>5. The Board of Directors must report to the General Meeting of Shareholders on its performances, in particular on the supervision of the Board of Directors over Enterprise Managers, Enterprise Executives in the financial year. The Board of Directors' report on performance submitting to the General Meeting of Shareholders must include the following contents:</p>	
<p>d. Activities of other Committees under the Board of Directors;</p>	<p><u>d. Activities of other Committees under the Board of Directors;</u></p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>
	<p><u>h. Submitting annual audited financial statements to the General Meeting of Shareholders;</u></p>	<p>Adding the content in accordance with point n, clause 2, Article 153 of the Law on Enterprises 2020 and point n, clause 2, Article 27 of the Model Charter under Circular 16/2020/TT-BTC.</p>
	<p><u>The Board of Directors shall ratify its resolution and decisions by voting at the meeting, solicitation of written opinion or email and other similar methods. Each member of the Board of Directors shall have one vote.</u></p>	<p>Adding the content in accordance with clause 3 Article 153 of the Law on Enterprises 2020.</p>
<p>7. When exercising their power and duties, the Board of Directors strictly abides by the provisions of law, this Charter and decisions of the General Meeting of Shareholders. In case the decision adopted by the Board of Directors contrary to the provisions of the law</p>	<p>7. When exercising their power and duties, the Board of Directors strictly abides by the provisions of law, this Charter and decisions of the General Meeting of Shareholders. In case the decision, <u>resolution</u> adopted by the Board of Directors contrary to the provisions of the law or this Charter causing damages to DHG</p>	<p>Adding the content in accordance with clause 4, Article 153 of the Law on Enterprises 2020.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>or this Charter causing damage to DHG PHARMA, the Board of Directors' members approving the decision must jointly bear personal responsibility for this decision and must compensate for damages to DHG PHARMA; Members who object to this decision will be exempt from liability.</p>	<p>PHARMA, the Board of Directors' members approving the decision, <u>resolution</u> must jointly bear personal responsibility for this decision, <u>resolution</u> and must compensate for damages to DHG PHARMA; the members that vote against such <u>resolution</u> or decision shall not be held responsible;</p> <p><u>In this case, DHG PHARMA's shareholders are entitled to request the court to suspend or invalidate the resolution or decision mentioned above.</u></p>	
<p>Article 30. Remuneration, salaries and other benefits of the Board of Directors' members</p> <p>1. Members of the Board of Directors (excluding authorized representatives) shall be entitled to remunerations for their assignments in their capacity as the Board of Directors' members. The total remuneration for the Board of Directors shall be decided by the General Meeting of Shareholders. This remuneration will be distributed to the members of the Board of Directors as agreed upon by the Board of Directors or equally divided in the case where no agreement is reached.</p>	<p>Article 30. Remunerations, salaries, and other benefits of the Board of Directors' members</p> <p><u>1. The Company shall pay remunerations, bonuses to the Board of Directors according to the Company's business performance.</u></p> <p>Members of the Board of Directors (excluding authorized representatives) shall be entitled to receive remunerations for their assignments as the Board of Directors' members. The total remuneration for the Board of Directors shall be decided by the General Meeting of Shareholders. This remuneration will be distributed to the members of the Board of Directors as agreed upon by the Board of Directors or equally divided in the case where no agreement is reached.</p>	<p>Adding the content in accordance with clause 1, Article 163 of the Law on Enterprises 2020 and clause 1, Article 28 of the Model Charter under Circular 116/2020/TT-BTC.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>2. The total amount of money paid to each member of the Board of Directors including: remuneration, expenses, commissions, right to purchase stock and other benefits received from DHG PHARMA, its subsidiaries, associates and other companies in which a member of the Board of Directors is the capital contributor representative, must be detailed in the annual report of DHG PHARMA. The remuneration of the Board of Directors' members must be shown separately in the Annual financial statements of DHG PHARMA.</p>	<p>2. The total amount of money paid to each member of the Board of Directors including: remunerations, expenses, commissions, right to purchase stock and other benefits received from DHG PHARMA, its subsidiaries, associates and other companies in which a member of the Board of Directors is the capital contributor representative, must be detailed in the annual report of DHG PHARMA.</p> <p><u>The remunerations of each member of the Board of Directors shall be recorded as the Company's expenses in accordance with regulations of law on corporate income tax in a separate section of the company's annual financial statements and shall be annually reported at the General Meeting of Shareholders.</u></p>	<p>Adding the content in accordance with clause 2, Article 163 of the Law on Enterprises 2020 and clause 2, Article 28 of the Model Charter under Circular 116/2020/TT-BTC.</p>
	<p><u>Members of the Board of Directors may have responsibility insurance purchased by the Company if it is approved by the General Meeting of Shareholders. This insurance does not cover the responsibilities of members of the Board of Directors relevant to violations against the law and the Company's Charter.</u></p>	<p>Adding the content in accordance with clause 6, Article 28 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>3. Any member of the Board of Directors who holds any executive position (including the Chairman or Deputy Chairman), or who works in committees of the Board of Directors or who performs other work which is, in the opinion of the Board of Directors, beyond the scope of normal tasks of a member of the Board of Directors, may be</p>	<p>3. Any member of the Board of Directors who holds any executive position (including the Chairman), or who works in committees of the Board of Directors or who performs other work which is, in the opinion of the Board of Directors, beyond the scope of normal tasks of a member of the Board of Directors, may be paid extra remuneration in the form of a lump sum wage on</p>	<p>Removing the Deputy Chairperson title to be consistent with the current Board of Directors' structure.</p> <p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
paid extra remuneration in the form of a lump sum wage on each time, salary, commission, profit percentage or other form as decided by the Board of Directors.	each time, salary, commission, profit percentage or other form as decided by the Board of Directors.	
4. Members of the Board of Directors shall be entitled to reimbursement of all costs of travel, meals, accommodation and other reasonable expenses paid by them when performing their responsibilities as the Board of Directors' members, including expenses arising out of attending the meetings of the General Meeting of Shareholders, the Board of Directors or committees of the Board of Directors, or the General Meeting of Shareholders.	4. Members of the Board of Directors shall be entitled to reimbursement of all costs of travel, meals, accommodation and other reasonable expenses paid by them when performing their responsibilities as the Board of Directors' members, including expenses arising out of attending the General Meeting of Shareholders, meetings of the Board of Directors or committees of the Board of Directors.	Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.
Article 31. The right to be informed of the Board of Directors' members	Article 31. The right to be informed of the Board of Directors' members	
2. Requested persons in Clause 1 of this Article are required to provide timely, complete and accurate information and documents in writing as requested by the members of the Board of Directors.	2. Requested persons in clause 1 of this Article are required to provide timely, complete and accurate information and documents in writing as requested by the members of the Board of Directors. <u>Orders, procedures to request and provide information shall be specified in the Ccompany's regulations.</u>	Adding the content in accordance with clause 2, Article 159 of the Law on Enterprises 2020.
Article 32. Components and term of the Board of Directors' members 2. The composition of the Board of Directors must be balanced between the number of members having knowledge and experience in law, finance and business operations of	Article 32. Components and term of the Board of Directors' members 2. The composition of the Board of Directors must be balanced between the number of members having knowledge and experience in law, finance and	Revising /Updating the content in accordance with Article 276 in Decree 155/2020/NQ-CP and clause 3, Article 26 of the Model Charter under Circular 116/2020/TT-BTC.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>DHG PHARMA and gender balance. Besides, must ensure that: (i) at least one-third (1/3) of the Board of Directors' members are independent members; (ii) At least one-third (1/3) of the Board of Directors' members are non-executive members.</p> <p>Must minimize the number of the Board of Directors' members who concurrently hold several executive titles of DHG PHARMA to ensure the independence of the Board of Directors.</p> <p>The minimum number of the independent Board of Directors' member and non-executive members of the Board of Directors is determined by the method of rounding down.</p>	<p>business operations of DHG PHARMA and gender balance. Besides, it must ensure that:</p> <p>(i) At least one-third (1/3) of the Board of Directors' members are non-executive members.</p> <p>It must minimize that the number of the Board of Directors' members concurrently holds several executive titles of DHG PHARMA to ensure the independence of the Board of Directors.</p> <p>(ii) The total independent board members must ensure the following regulation:</p> <p><u>a. Having at least 01 independent board member if DHG PHARMA has from 03 to 05 members of the Board of Directors.</u></p> <p><u>b. Having at least 02 independent board members if DHG PHARMA has from 06 to 08 members of the Board of Directors.</u></p> <p><u>c. Having at least 03 independent board members if DHG PHARMA has from 09 to 11 members of the Board of Directors.</u></p>	
<p>3. The term of the Board of Directors is five (05) years. The term of a member of the Board of Directors shall not exceed five (05) years; members of the Board of Directors may be re-elected for an unlimited number of terms by cumulative voting.</p>	<p>The term of the Board of Directors is five (05) years. The term of a member of the Board of Directors shall not exceed five (05) years; members of the Board of Directors may be re-elected for an unlimited number of terms by cumulative voting. <u>An individual can only be elected as an independent board member of a company for no more than 2 consecutive terms.</u></p>	<p>Adding the content in accordance with clause 2 Article 154 of the Law on Enterprises 2020 and clause 2 Article 26 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>Article 33. Candidacy and nomination of the Board of Directors' members</p>	<p>Article 33. Candidacy and nomination of the Board of Directors' members</p>	<p>Adding the content in accordance with clause 5, Article 115 of the Law on Enterprises 2020 and clause 2,</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>1. Shareholders who are holding 5% or more of their voting shares for at least six (06) consecutive months have the right to add up the number of voting rights of each other to nominate candidates for the Board of Directors. A shareholder or a group of shareholders who are holding from 5% to under 10% of the total number of voting shares shall be entitled to nominate one (01) candidate; from 10% to under 30% may nominate up to two (02) candidates; from 30% to under 40% may nominate up to three (03) candidates; from 40% to under 50% shall be entitled to nominate up to four (04) candidates; from 50% to under 60% shall be entitled to nominate up to five (05) candidates; from 60% to under 70% shall be entitled to nominate up to six (06) candidates; from 70% to under 80% shall be entitled to nominate up to seven (07) candidates and from 80% to under 90% shall be entitled to nominate up to eight (08) candidates.</p>	<p>1. Shareholders who are holding 5% or more of their voting shares have the right to add up the number of voting rights of each other to nominate candidates for the Board of Directors. A shareholder or a group of shareholders who are holding from 5% to under 10% of the total number of voting shares shall be entitled to nominate one (01) candidate; from 10% to under 30% may nominate up to two (02) candidates; from 30% to under 40% may nominate up to three (03) candidates; from 40% to under 50% shall be entitled to nominate up to four (04) candidates; from 50% to under 60% shall be entitled to nominate up to five (05) candidates; from 60% to under 70% shall be entitled to nominate up to six (06) candidates; from 70% to under 80% shall be entitled to nominate up to seven (07) candidates and from 80% to under 90% shall be entitled to nominate up to eight (08) candidates.</p>	<p>Article 25 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>Article 34. Standards, conditions, rights, and obligations of the Board of Directors' members</p> <p>1. Members of the Board of Directors must have the following standards and conditions:</p>	<p>Article 34. Standards, conditions, rights, and obligations of the Board of Directors' members</p> <p>1. Members of the Board of Directors must have the following standards and conditions:</p>	

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
a. Have full civil act capacity and not being subjects banned from the management of enterprises according to the provisions of Clause 2, Article 18 of the Law on Enterprises;	a. Have full civil act capacity and not being subjects banned from the management of enterprises according to the provisions of <u>clause 2, Article 17</u> of the Law on Enterprises;	Revising/ Updating the reference in accordance with the Law on Enterprises 2020.
c. A member of the Board of Directors can concurrently be a member of the Board of Directors of another company, but not be a member of the Board of Directors of over five (05) other companies from 01 August 2019 .	c. A member of the Board of Directors can concurrently be a member of the Board of Directors of another company, but not be a member of the Board of Directors of over five (05) other companies.	Adding the content in accordance with point c, clause 1, Article 155 of the Law on Enterprises 2020 and clause 3, Article 275 of Decree 155/2020/ND-CP.
3. In addition to the powers and duties mentioned in Clause 2 of this Article, independent members of the Board of Directors in charge of the Audit Committee must also supervise and control the management of the Company. The mechanism for implementing this function is stipulated in the Internal Regulation on Corporate Governance.	3. In addition to the powers and duties mentioned in clause 2 of this Article, independent board members in charge of the Audit Committee must also supervise and control the management of the Company. The mechanism for implementing this function is stipulated in the Internal Regulation on Corporate Governance.	Revising the Vietnamese name of Audit Committee to be consistent with the change of Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.
<p>Article 36. Chairman, Deputy Chairman of the Board of Directors</p> <p>1. The Board of Directors must select from among the members of the Board of Directors to elect a Chairman and a Deputy Chairman.</p> <p>Unless otherwise decided by the General Meeting of Shareholders, that the Chairman of the Board of Directors concurrently holds the position of General Director, it must be</p>	<p>Article 36. Chairperson of the Board of Directors</p> <p>1. The Board of Directors shall select from among the members of the Board of Directors to elect a Chairperson.</p> <p>The Chairperson of the Board of Directors shall not simultaneously hold the position of General Director.</p> <p>The Chairperson of the Board of Directors may be dismissed in accordance with the decision of the Board of Directors. The Chairperson of the Board of Directors</p>	Adding the content in accordance with clause 1 and 2, Article 156 of the Law on Enterprises 2020 and clause 1, 2 Article 29 of the Model Charter under Circular 116/2020/TT-BTC. Removing the “Deputy Chairperson of the Board of Directors” title to be consistent with the current Board of Directors’ structure.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>approved annually at the Annual General Meeting of Shareholders.</p> <p>From 01 August 2020, the Chairman of the Board of Directors does not concurrently hold the post of General Director.</p> <p>The Chairman of the Board of Directors may be dismissed in accordance with the decision of the Board of Directors. The Chairman of the Board of Directors who is dismissed shall continue to be a member of the Board of Directors.</p>	<p>who is dismissed shall continue to be a member of the Board of Directors.</p>	
<p>2. The Chairman of the Board of Directors shall have the following rights and obligations:</p>	<p>2. The Chairperson of the Board of Directors shall have the following rights and obligations:</p>	
<p>e. To organize the adoption of the Board of Directors' resolution;</p>	<p>e. To organize the adoption of the Board of Directors' resolutions and <u>decisions</u>;</p>	<p>Adding the content in accordance with point c, clause 3, Article 156 of the Law on Enterprises 2020 and point c, clause 3, Article 29 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>f. To supervise the implementation of the Board of Directors' resolution;</p>	<p>f. To supervise the implementation of the Board of Directors' resolutions and <u>decisions</u>;</p>	<p>Adding the content in accordance with point d, clause 3, Article 156 of the Law on Enterprises 2020 and point d, clause 3, Article 29 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>3. The Deputy Chairman of the Board of Directors has the following rights and duties:</p>		<p>Removing the "Deputy Chairperson of the Board of Directors" title to be</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>a. Has the rights and duties mentioned in Clause 2 Article 34 of this Charter.</p> <p>b. To comply with the obligations of the Enterprise Manager of the Company stipulated in Section D Chapter III of this Charter.</p> <p>c. To perform tasks assigned by the Board of Directors on behalf of the Chairman of the Board of Directors or perform tasks authorized by the Chairman of the Board of Directors in accordance with Clause 4 of this Article.</p> <p>d. To counsel, advise on matters related to the strategy for investment in production, business expansion and personnel under the appointment and dismissal of the Board of Directors</p>		<p>consistent with the current Board of Directors' structure.</p>
<p>4. If the Chairman of the Board of Directors is absent without authorizing another member of the Board of Directors using power of attorney, the Deputy Chairman shall exercise the rights and duties of the Chairman of the Board of Directors. If the Chairman of the Board of Directors is absent but authorizes another member of the Board of Directors using the power of attorney, if such member is not the Deputy Chairman, this must be notified simultaneously to all members of the Board of Directors, the Person in charge of</p>	<p>4. If the Chairperson of the Board of Directors is absent or unable to perform his/her duties, <u>he/she must authorize in writing another member to exercise the rights and duties of the Chairperson of the Board of Directors. Such authorization</u> must be notified simultaneously to all members of the Board of Directors, the Person in charge of corporate governance, and the Secretary of the Board of Directors of DHG PHARMA.</p> <p><u>In case no one is authorized or the Chairperson of the Board of Directors is dead, missing, held in police custody, imprisoned, detained in a mandatory rehabilitation center or correctional institution, has fled</u></p>	<p>Adding the content in accordance with clause 4 Article 156 of the Law on Enterprises 2020 and clause 5, Article 29 of the Model Charter under Circular 116/2020/TT-BTC.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
corporate governance, and the Secretary of the Board of Directors of DHG PHARMA.	<u>the residence, has limited capacity or is incapacitated, has difficulties controlling his/her behaviors, is prohibited by the Court from holding certain positions or doing certain works, the remaining members shall elect one of them to hold the position of Chairperson of the Board of Directors under the majority rule until a new decision is issued by the Board of Directors.</u>	
5. In case both of the Chairman and the Deputy Chairman are temporarily unable to perform their duties for any reason, the Board of Directors may appoint another person among them to carry out the duties of the Chairman in accordance with the majority principle.		This content has been merged to clause 4 of this Article.
6. Where the Chairman and the Deputy Chairman of the Board of Directors resigns or is dismissed or removed, the Board of Directors must elect any replacement within a period of ten (10) days.	5. If the Chairperson of the Board of Directors resigns or is dismissed or removed, the Board of Directors must elect any replacement within a period of ten (10) days.	Removing the “Deputy Chairperson of the Board of Directors” title to be consistent with the current Board of Directors’ structure.
Article 37. Meetings of the Board of Directors	Article 37. Meetings of the Board of Directors	
	<u>In case the voting form is sent to the meeting by mail, they must be put in sealed envelopes and delivered to the Chairperson of the Board of Directors at least 01 hour before the opening hour. The voting form shall only be opened in the presence of the meeting participants.</u>	Adding the content in accordance with clause 10, Article 157 of the Law on Enterprises 2020 and clause 10, Article 30 of the Model Charter under Circular 116/2020/TT-BTC.
16. Legal value of actions: The actions enforcing the decisions of the Board of	16. Legal value of actions: The actions enforcing the decisions of the Board of Directors or Committee under	Revising the Vietnamese name of Committees to unify the names of

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>Directors or Committee under the Board of Directors, or any person as a member of the committees of the Board of Directors shall be legally valid even in cases where the election and appointment of members of committees or members of the Board of Directors occur errors.</p>	<p>the Board of Directors, or any person as a member of the committees of the Board of Directors shall be legally valid even in cases where the election and appointment of members of committees or members of the Board of Directors occur errors.</p>	<p>Committees under the Board of Directors.</p>
<p>Article 39. The Committees of the Board of Directors</p> <p>1. Pursuant to the approval of General Meeting of Shareholders, the Board of Directors establishes the affiliated committees to support the operations of the Board of Directors, including: Strategic Committee, Nomination Committee, Audit Committee, and other committees if it deems necessary.</p> <p>If DHG PHARMA has not established or shall not establish the Nomination Committee, then the Board of Directors shall designate an independent Board of Directors' member to help the Board of Directors to carry out the nomination and remuneration activities.</p>	<p>Article 39. Committees of the Board of Directors</p> <p>1. Except for Audit Committee to be approved by the General Meeting of Shareholders, the Board of Directors can establish affiliated committees to be in charge of development policies, nomination, remuneration, risk management, <u>and other committees if necessary.</u></p> <p>If DHG PHARMA has not established or shall not establish a Nomination Committee, then the Board of Directors shall designate an independent board member to help the Board of Directors carry out the nomination and remuneration activities.</p>	<p>Adding the content in accordance with Article 161 of the Law on Enterprises 2020 and clause 1, Article 31 of the Model Charter under Circular 116/2020/TT-BTC</p>
<p>2. The number of members of the committee is decided by the Board of Directors, but there should be at least three (03) members including members of the Board of Directors and external members. Independent Board</p>	<p>2. The number of committees' members is decided by the Board of Directors, but there should be at least three (03) members including members of the Board of Directors and external members. Independent board members/non-executive members of the Board of</p>	<p>Adding the content in accordance with Article 161 of the Law on Enterprises 2020 and clause 1, Article 31 of the Model Charter under Circular 116/2020/TT-BTC</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>of Directors' members/non-executive members of the Board of Directors should occupy a majority in the committees and one of these members shall be appointed as Head of the committees under the decisions of the Board of Directors.</p> <p>Standards of members of the Audit Committee are stipulated in Article 40 of this Charter.</p> <p>The activities of committees must comply with the regulations of the Board of Directors. Resolutions of the committees are effective only when a majority of the members attended and voted at the committees' meeting are members of the Board of Directors.</p>	<p>Directors should occupy a majority in the committees and one of these members shall be appointed as the <u>Chairperson</u> of the committees under the decisions of the Board of Directors.</p> <p>Standards of members of the Audit Committee are stipulated in Article 40 of this Charter.</p> <p>The activities of Committees must comply with the regulations of the Board of Directors. Resolutions of the Committees are effective only when a majority of the members attended and voted at the committees' meeting are members of the Board of Directors.</p>	
<p>3. The implementation of the decisions of the Board of Directors or of committees under the Board of Directors, or of any person as a member of committees of the Board of Directors must comply with the applicable laws and regulations in this Charter.</p>	<p>3. The implementation of the decisions of the Board of Directors or of committees under the Board of Directors, or of any person as a member of committees of the Board of Directors must comply with the applicable laws and regulations in this Charter.</p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>
<p>4. The Board of Directors regulates the establishment, responsibilities of the committees and the responsibilities of each member of the committees in detail as stipulated in Clause 1 of this Article.</p>	<p>4. The Board of Directors regulates the establishment, responsibilities of the committees and the responsibilities of each member of the committees in detail as stipulated in clause 1 of this Article.</p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>Article 40. Audit Committee</p> <p>1. Pursuant to the Resolution of the General Meeting of Shareholders about the organizational structure of the Company, the Board of Directors shall decide to establish Audit Committee and promulgate Internal Audit Regulation of the Company. The Audit Committee has three (03) to five (05) members appointed by the Board of Directors.</p>	<p>Article 40. Audit Committee</p> <p>1. Pursuant to the Resolution of the General Meeting of Shareholders about the organizational structure of the Company, the Board of Directors shall decide to establish an Audit Committee. The Audit Committee has three (03) to five (05) members appointed by the Board of Directors.</p>	<p>Adding the content in accordance with clause 1, Article 161 of the Law on Enterprises 2020 and clause 1, Article 31 of the Model Charter under Circular 116/2020/TT-BTC; and clause 1 and 2, Article 282 of Decree 155/2020/ND-CP.</p>
<p>2. Members of the Audit Committee must satisfy the following standards, conditions:</p>	<p>2. Members of the Audit Committee must satisfy the following standards, conditions:</p>	<p>Revising the Vietnamese name of Audit Committee in accordance with Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.</p>
<p>3. The Head of the Audit Committee is appointed and nominated by the Board of Directors. The Head of Audit Committee must satisfy the following standards and conditions:</p>	<p>3. The <u>Chairperson</u> of Audit Committee is appointed and nominated by the Board of Directors. The <u>Chairperson</u> of Audit Committee must satisfy the following standards and conditions:</p>	<p>Revising the Vietnamese title of the Chairperson of Audit Committee in accordance with Article 161 of the Law on Enterprises 2020.</p>
<p>Article 41. Powers and responsibilities of Audit Committee</p> <p>1. Powers and responsibilities</p>	<p>Article 41. Powers and responsibilities of Audit Committee</p> <p>1. Powers and responsibilities</p>	<p>Revising the Vietnamese name of Audit Committee in accordance with Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.</p>
<p>e. The Audit Committee must report, explain the issues as required by the Board of Directors. The inspection of the Audit Committee stipulated in this Clause shall not</p>	<p>e. The Audit Committee must report, explain the issues as required by the Board of Directors. The inspection of the Audit Committee stipulated in this clause shall not</p>	<p>Revising the Vietnamese name of Audit Committee in accordance with Article 161 of the Law on Enterprises</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
interfere with the usual operation, shall not interrupt the operation of the Company;	interfere with the usual operation, shall not interrupt the operation of the Company;	2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.
g. When detecting members of the Board of Directors, General Director violated the obligations of the Company's Enterprise Managers stipulated in Article 160 of the Law on Enterprises, Article 49 and Article 50 of this Charter, the violator must be requested to terminate the violation, and simultaneously written notice must be immediately sent to the Board of Directors to handle;	g. When detecting members of the Board of Directors, General Director violated the obligations of the Company's Enterprise Managers stipulated in <u>Article 165</u> of the Law on Enterprises, Article 49 and Article 50 of this Charter, the violator must be requested to terminate the violation, and simultaneously a written notice must be immediately sent to the Board of Directors to handle;	Revising/ Updating the reference according to the Law on Enterprises 2020.
	<u>Supervise the Company's compliance with law, requests of the authorities and the company's internal regulations;</u>	Adding the content in accordance with point g, clause 3, Article 161 of the Law on Enterprises 2020 and Article 283 of Decree 155/2020/ND-CP.
	<u>Monitor and evaluate the independence and objectivity of the audit firm and effectiveness of the audit, especially when the company uses non-audit services of the audit company.</u>	Adding the content in accordance with point e, clause 3, Article 161 of the Law on Enterprises 2020 and Article 283 of Decree 155/2020/ND-CP.
l. In case of hiring the independent auditor, the Audit Committee is responsible for the audit and accounting activities of the Company as follows:	l. In case of hiring an independent auditor, the Audit Committee is responsible for the auditing and accounting activities of the Company as follows:	Revising the Vietnamese name of Audit Committee in accordance with Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.
2. The Audit Committee is entitled to utilize the independent consultant to perform the assigned tasks.	2. The Audit Committee is entitled to utilize the independent consultant to perform the assigned tasks.	Revising the Vietnamese name of Audit Committee to be consistent with the change of Article 161 of the

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
		Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.
3. Members of the Board of Directors, General Director, other Enterprise Managers and Enterprise Executives must provide all information and documents related to the Company's operations requested by the Audit Committee.	3. Members of the Board of Directors, General Director, other Enterprise Managers, and Enterprise Executives must provide all information and documents related to the Company's operations requested by the Audit Committee.	Revising the Vietnamese name of Audit Committee in accordance with Article 161 of the Law on Enterprises 2020 and Article 282, 283, 284 of Decree 155/2020/ND-CP.
	<p><u>4. The independent board member in the Audit Committee is responsible for reporting his/her committee's activities at the Annual General Meeting of Shareholders. Such report must include the following contents: :</u></p> <p><u>a) Remunerations, operating costs and other benefits of the Audit Committee and each of its members. The remunerations shall be presented as a separate item in the annual financial statements of DHG PHARMA.</u></p> <p><u>b) Summaries of meetings of the Audit Committee, its verdicts and proposals;</u></p> <p><u>c) Results of supervision of the Company's financial statements, finance and operation;</u></p> <p><u>d) Evaluation of transactions between the Company, subsidiaries and companies over 50% charter capital of which is held by the Company with members of the Board of Directors, General Director, other executives of the Company and their related persons; transactions between the Company with companies whose founders or managers are members of the Board of</u></p>	Adding, explaining the content in accordance with Article 46 of the Model Charter under Circular 116/2020/TT-BTC.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
	<u>Directors, General Director or executives over the last 03 years from the transaction date;</u> <u>dd) Evaluation of the Company's internal control and risk management system;</u> <u>e) Monitoring results over the Board of Directors, the General Director and other Executives of the Company;</u> <u>f) Cooperation between the Audit Committee with the Board of Directors, General Director and shareholders;</u> <u>g) Other contents</u>	
Article 42. Person in charge of corporate governance of DHG PHARMA	Article 42. Person in charge of corporate governance of DHG PHARMA	
3. The person in charge of corporate governance of DHG PHARMA has the following powers and obligations:	3. The person in charge of corporate governance of DHG PHARMA has the following powers and obligations:	Adding the content in accordance with point h, clause 3, Article 32 of the Model Charter under Circular 116/2020/TT-BTC and point h, clause 3, Article 281 of Decree 155/2020/ND-CP.
	<u>Being a contact person with stakeholders;</u>	
Section C: EXECUTIVE BOARD	Section C: EXECUTIVE BOARD	
Article 44. Organization of executive apparatus DHG PHARMA promulgates an organizational system of executive management in which the Executive Board shall be responsible for and under the management, direction, and supervision of the Board of Directors. The Executive Board of DHG PHARMA has one General Director,	Article 44. Organization of executive apparatus DHG PHARMA promulgates an organizational system of executive management in which the Executive Board shall be responsible for and under the management, direction, and supervision of the Board of Directors. The Executive Board of DHG PHARMA has one General Director, <u>one Chief Operating Officer</u> , Deputy General Directors, one Chief Accountant and <u>other executive positions</u> who are appointed by the	Adding the content in accordance with Article 33 of the Model Charter under Circular 116/2020/TT-BTC and adding the title “Chief Operating Officer” in accordance with the Company’s reality.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>some Deputy General Directors, one Chief Accountant and the Enterprise Executives who are appointed by the Board of Directors. The General Director and Deputy General Directors may concurrently hold the position of the members of the Board of Directors that are appointed, dismissed or removed through a legitimate ratified resolution by the Board of Directors.</p>	<p>Board of Directors. The General Director, <u>the Chief Operating Officer</u>, and Deputy General Directors may concurrently hold the position of the members of the Board of Directors that are appointed or dismissed through a legitimate ratified resolution, <u>decision</u> by the Board of Directors.</p>	
<p>Article 45. Other Enterprise Executives</p>	<p>Article 45. Enterprise Executives <u>of the Company</u></p>	
	<p><u>Salaries of executives shall be recorded in the Company's operating costs in accordance with regulations of law on corporate income tax, presented in a separate section of the Company's annual financial statement and reported at the Annual General Meeting of Shareholders.</u></p>	<p>Adding the content in accordance with clause 4, Article 34 of the Model Charter under Circular 116/2020/TT-BTC</p>
<p>Article 46. The General Director 4. The General Director has the following powers and obligations:</p>	<p>Article 46. General Director 4. The General Director has the following powers and obligations: <u>Promulgating regulations except for the regulations in item (iv), point b, clause 4, Article 29 of this Charter.</u></p>	<p>Adding the content to match the current practices of the Company.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>Article 47. The Deputy General Directors</p> <p>1. The Board of Directors shall appoint members of the Board of Directors or shareholders or persons hired or recruited by the Board of Directors under the contract to be the Deputy General Directors. The Deputy General Director shall have the same working term as the General Director.</p> <p>2. The Deputy General Director has the following powers and obligations:</p> <p>f. Complying with obligations of Enterprise Managers stipulated in Article 160 of the Law on Enterprises, Enterprise Executives stipulated in Section D, Chapter III of this Charter.</p>	<p>Article 47. Chief Operating Officer and Deputy General Directors</p> <p>1. <u>Chief Operating Officer</u> and Deputy General Directors can be appointed by members of the Board of Directors or shareholders, or can be hired or recruited by the Board of Directors under contract. <u>The Chief Operating Officer</u> and Deputy General Directors shall have the same working term as the General Director.</p> <p>2. Chief Operating Officer and Deputy General Directors have the following powers and obligations:</p> <p>f. Complying with obligations of Enterprise Managers stipulated in <u>Article 165</u> of the Law on Enterprises, Enterprise Executives stipulated in Section D, Chapter III of this Charter.</p>	<p>Adding the Chief Operating Officer title to match the organizational structure of the Company.</p> <p>Revising/ Updating the reference in accordance with the Law on Enterprises 2020.</p>
<p>Section D: RESPONSIBILITIES OF MEMBERS OF THE BOARD OF DIRECTORS, GENERAL DIRECTOR AND ENTERPRISE EXECUTIVES</p>	<p>Section D: RESPONSIBILITIES OF MEMBERS OF THE BOARD OF DIRECTORS, GENERAL DIRECTOR AND ENTERPRISE EXECUTIVES</p>	
<p>Article 49. Responsibility to be prudent</p>	<p>Article 49. Duty of care</p>	
<p>Members of the Board of Directors, the General Director and the entrusted Enterprise Executives are responsible for the execution of their duties, and the members of committees of the Board of Directors, honestly for the best interests of DHG PHARMA and with the prudent level that a careful person must have upon taking on the same position and in similar situation.</p>	<p>Members of the Board of Directors, members of the Committees under the Board of Directors, the General Director, and the entrusted Enterprise Executives are responsible for the execution of their duties honestly and for the best interests of DHG PHARMA and with the prudent level that a careful person must have upon taking on the same position and in similar situation.</p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
	<u>2. Being loyal to the interests of DHG PHARMA; Not abusing power, position or using information, know-how, business opportunities, and other assets of DHG PHARMA for personal gain or serving the interests of any other organizations or individuals;</u>	Adding the content in accordance with point a, clause 1, Article 71 of the Law on Enterprises 2020 and Article 48 of the Model Charter under Circular 116/2020/TT-BTC.
	<u>3) Promptly, accurately and fully notifying DHG PHARMA of the enterprises that they own or have shares/contributed capital or that their related persons own, jointly own or have separate controlling shares/contributed capital.</u>	Adding the content in accordance with point c, clause 1, Article 71 of the Law on Enterprises 2020 and Article 48 of the Model Charter under Circular 116/2020/TT-BTC.
Article 50. Responsibility to be honest and avoid conflicts of interests 1. Members of the Board of Directors, members of the committees under the Board of Directors, the General Director and Enterprise Executives must publish the related interests in compliance with regulations of the Law on Enterprises and other relevant laws.	Article 50. Responsibility to be honest and avoid conflicts of interests 1. Members of the Board of Directors, members of the committees under the Board of Directors, the General Director and Enterprise Executives must publish the related interests in compliance with regulations of the Law on Enterprises and other relevant laws.	Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.
3. Members of the Board of Directors, members of the committees under the Board of Directors, the General Directors and other Enterprise Executives have the obligation to inform the Board of Directors of the transactions between DHG PHARMA, subsidiaries of DHG PHARMA and companies with fifty percent (50%) or more of charter capital controlled by DHG PHARMA with the above members or their	3. Members of the Board of Directors, members of the committees under the Board of Directors, the General Directors and other Enterprise Executives have the obligation to inform the Board of Directors of the transactions between DHG PHARMA, subsidiaries of DHG PHARMA and companies with fifty percent (50%) or more of charter capital controlled by DHG PHARMA with the above members or their related persons in compliance with provisions of law. DHG PHARMA must publish information about the transactions of the	Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
related persons in compliance with provisions of law. DHG PHARMA must publish information about the transactions of the above-mentioned persons which have been approved by the General Meeting of Shareholders or the Board of Directors in accordance with the Securities Law on information disclosure.	above-mentioned persons which have been approved by the General Meeting of Shareholders or the Board of Directors in accordance with the Securities Law on information disclosure.	
5. Members of the Board of Directors, members of committees under the Board of Directors, the General Director, the Enterprise Executives and the related persons to the above members shall not use information that is not permitted for publication of DHG PHARMA or disclosure to other people to carry out the relevant transactions.	5. Members of the Board of Directors, members of committees under the Board of Directors, the General Director, the Enterprise Executives and the related persons to the above members shall not use information that is not permitted for publication of DHG PHARMA or disclosure to other people to carry out the relevant transactions.	Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.
Article 52. Transactions with shareholders, Enterprise Managers, Enterprise Executives and their related persons	Article 52. Transactions with shareholders, Enterprise Managers, Enterprise Executives, and their related persons	
2. DHG PHARMA must not provide its shareholders that are organizations and their related persons that are individuals with loans or guarantee, unless the shareholder is a subsidiary whose share or stakes are not held by the State and has contributed capital or purchased the shares of DHG PHARMA before 01 July 2015 as specified in Clause 6,	2. DHG PHARMA must not provide its shareholders that are organizations and their related individuals with loans or guarantee, except for the cases specified in <u>Article 293 of Decree 155/2020/ND-CP dated 31 December 2020 by the Government detailing the implementation of a number of articles of the Law on Securities.</u>	Adding the content according to Article 293 of Decree 155/2020/ND-CP.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>Article 16 of the Decree No.96/2015/ND-CP dated 19 October 2015 of the government specifying the number of articles of the Law on Enterprises.</p>		
<p>4. DHG PHARMA must not make the following transactions unless they are approved by the General Meeting of Shareholders:</p>	<p>4. DHG PHARMA must not make the following transactions unless they are approved by the General Meeting of Shareholders:</p>	
<p>a. Grant of loans or guarantees to the members of the Board of Directors, members of the committees under the Board of Directors, General Director, Enterprise Managers, Enterprise Executives and the individuals and organizations related to them, unless DHG PHARMA and organizations related to its shareholders are companies in the same group or companies operating in a group of companies, including parent companies - subsidiaries, economic groups, and the relevant law specifies otherwise.</p>	<p>a. Grant of loans or guarantees to the members of the Board of Directors, members of the committees under the Board of Directors, General Director, Enterprise Managers, Enterprise Executives and the individuals and organizations related to them, unless DHG PHARMA and organizations related to its shareholders are companies in the same group or companies operating in a group of companies, including parent companies - subsidiaries, economic groups, and the relevant law specifies otherwise.</p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>
<p>b. Any transaction that has the total value of twenty-five percent (25%) or more of the total value of assets recorded in DHG PHARMA's latest financial statement between DHG PHARMA and one of the following entities: (i) Members of the Board of Directors, members of the committees under the Board of Directors, General Director, Enterprise</p>	<p>b. Any transaction that has the total value of twenty-five percent (25%) or more of the total value of assets recorded in DHG PHARMA's latest financial statement between DHG PHARMA and one of the following entities: (i) Members of the Board of Directors, members of the committees under the Board of Directors, General</p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
Managers, Enterprise Executives and their related persons;	Director, Enterprise Managers, Enterprise Executives and their related persons;	
(iii) Enterprises related to the subjects specified in Clause 2, Article 159 of the Law on Enterprises.	(iii) Enterprises related to the subjects specified in <u>clause 2, Article 164</u> of the Law on Enterprises.	Revising/ Updating the reference in accordance with the Law on Enterprises 2020.
<p>6. The contract or transaction in clause 4, 5 of this Article is considered by an independent consultant to be fair and reasonable in all respects in relation to the shareholders of DHG PHARMA at the time of this transaction or contract is approved by the Board of Directors or the General Meeting of Shareholders.</p> <p>Members of the Board of Directors, members of the committees under the Board of Directors, the General Director, the Enterprise Executives, the Enterprise Managers and other organizations and individuals related to the above members must not use DHG PHARMA's information which has not yet been permitted to be disclosed, or must not disclose information to others in order to implement related transactions.</p>	<p>6. The contract or transaction in clause 4, 5 of this Article is considered by an independent consultant to be fair and reasonable in all respects in relation to the shareholders of DHG PHARMA at the time of this transaction or contract is approved by the Board of Directors or the General Meeting of Shareholders.</p> <p>Members of the Board of Directors, members of the committees under the Board of Directors, the General Director, the Enterprise Executives, the Enterprise Managers and other organizations and individuals related to the above members must not use DHG PHARMA's information which has not yet been permitted to be disclosed, or must not disclose information to others in order to implement related transactions.</p>	Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
	<p>7. The transactions specified in point b clause 4 and clause 5 of this Article <u>between the Company with one or many members of the Board of Directors, the General Director, other executives, and their related organizations and persons shall not be invalidated in the following cases:</u></p> <p>a. <u>As for transactions prescribed at clause 5 of this Article whose values do not exceed twenty five percent (25%) of the total assets recorded in the latest financial statements, important contents of contracts or transactions as well as relationships and interests of members of the Board of Directors, the General Director, other executives have been reported to the Board of Directors and are approved by the majority of the members of the Board of Directors without relevant interests;</u></p> <p>b. <u>For transactions valued from twenty five percent (25%) ore more at point b, clause 4 of this Article or a transaction occurs within 12 months from the first transaction date valued from twenty five percent (25%) or more of the total assets recorded in the most recent financial statements, important contents of this transaction as well as the relationship and interests of members of the Board of Directors, General Director, other executives have been announced to shareholders and are approved by the General Meeting of Shareholders by votes of shareholders without relevant interests.</u></p>	<p>Adding the content in accordance with clause 6, Article 47 of the Model Charter under Circular 116/2020/TT-BTC.</p>
<p>Article 54. Responsibilities for damage and compensation</p>	<p>Article 54. Responsibilities for damage and compensation</p>	

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>2. Compensation: DHG PHARMA shall make compensation for those who have, are or may become a party involved in the complaints, lawsuits and prosecution that have been being or may be made including civil and administrative cases (and not the lawsuits initiated by DHG PHARMA as the petitioner) if those persons were or are the Board of Directors' members, Enterprise Managers, Enterprise Executives, employees, or representatives authorized by DHG PHARMA (or subsidiaries of DHG PHARMA), or those persons have been implementing at the request of DHG PHARMA (or subsidiaries of DHG PHARMA) as the Board of Directors' members, Enterprise Managers, Enterprise Executives, employees, or authorized representatives of the Company, Partner, association of companies, trustee or another juridical person. The compensation expenses include accrued expenses (including attorneys fees), judgment expenses, fines, amounts payable arising in reality or are considered to be reasonable when dealing with these cases in the framework of the law allowed, provided that they have acted with honesty, prudence, diligence and professional competence, for the benefits without being against the highest</p>	<p>2. Compensation: DHG PHARMA shall make compensation for those who have, are or may become a party involved in the <u>complaints, lawsuits and prosecution</u> (including civil and administrative cases in which the Company is not the petitioner) if those persons were or are the Board of Directors' members, Enterprise Managers, Enterprise Executives, employees, or representatives authorized by DHG PHARMA (or subsidiaries of DHG PHARMA), or those persons have been implementing at the request of DHG PHARMA (or subsidiaries of DHG PHARMA) as the Board of Directors' members, Enterprise Managers, Enterprise Executives, employees, or authorized representatives of the Company, partner, joint venture, trust <u>or other legal entity, who performed or are performing their duties as authorized by the Company, act in a lawful, honest and prudent manner for the Company's interests, and there is no evidence that they fail to fulfill their duties.</u></p> <p>The compensation expenses include arising expenses (including attorneys fees), judgment expenses, fines, amounts payable arising in reality or are considered to be reasonable when dealing with these cases in the framework of the law allowed, provided that they have acted with honesty, prudence, diligence and professional competence, for the benefits without being against the highest interests of DHG PHARMA, on the basis of compliance with the law and there is no evidence to confirm those persons have violated their responsibilities. DHG PHARMA can buy insurance for</p>	<p>Adding the content in accordance with Article 165 of the Law on Enterprises and clause 2, Article 48 of the Model Charter under Circular 116/2020/TT-BTC.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
interests of DHG PHARMA, on the basis of compliance with the law and there is no evidence to confirm those persons have violated their responsibilities. DHG PHARMA can buy insurance for these people to avoid the compensation liability above mentioned.	these people to avoid the compensation liability above mentioned.	
Chapter IV: FINANCE - ACCOUNTING, FUND AND PROFIT DISTRIBUTION	Chapter IV: FINANCE - ACCOUNTING, FUNDS AND PROFIT DISTRIBUTION	
Article 56. Accounting system 1. The accounting system used by DHG PHARMA shall be Vietnamese Accounting System (VAS) or another accounting system approved by the Minister of Finance.	Article 56. Accounting system 1. The accounting system used by DHG PHARMA shall be the enterprise accounting system or a specific accounting system promulgated or approved by a competent agency.	
3. DHG PHARMA uses the Vietnamese dong as the official currency in accounting.	3. DHG PHARMA uses the Vietnamese dong as the official currency in accounting. <u>If the Company's transactions primarily use a foreign currency, the Company may use it as accounting currency, take legal responsibility and notify its supervisory tax authority.</u>	Adding the content in accordance with clause 3, Article 54 of the Model Charter under Circular 116/2020/TT-BTC
Article 57. Profit distribution	Article 57. Profit distribution	
5. Where any dividend payment or other payments relating to one class of shares shall be paid by cash, DHG PHARMA must make such payment in Vietnamese dong and can pay by check or by postal order to the registered address of the beneficiary and in case of arising risks (from the registered address of shareholder), the shareholder must bear it. In addition, dividend payments or other cash payments related to a class of	5. Where any dividend payment or other payments relating to one class of shares shall be paid by cash, DHG PHARMA must make such payment in Vietnamese dong and can pay by check or by postal order to the registered address of the beneficiary and in case of arising risks (from the registered address of shareholder), the shareholder must bear it. In addition, dividend payments or other cash payments related to a class of shares may be paid by bank transfer when DHG PHARMA has detailed bank information of	Adding the content in accordance with clause 4, Article 51 of the Model Charter under Circular 116/2020/TT-BTC, revising name of the depository center to match actual practice.

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>shares may be paid by bank transfer when DHG PHARMA has detailed bank information of shareholder to allow DHG PHARMA to make direct transfers to the shareholder's bank account. In case that DHG PHARMA makes a bank transfer based on the exact banking detail provided by a shareholder but such shareholder cannot receive money, DHG PHARMA shall not be liable for amount which it has transferred to the shareholder entitled to such amount. Dividend payment for shares listed on the Stock Exchange may be made through a securities company or a Depository Center.</p>	<p>shareholder to allow DHG PHARMA to make direct transfers to the shareholder's bank account. In case that DHG PHARMA makes a bank transfer based on the exact banking detail provided by a shareholder but such shareholder cannot receive money, DHG PHARMA shall not be liable for amount which it has transferred to the shareholder entitled to such amount. Dividend payment for shares listed on the Stock Exchange may be made through a securities company or <u>Vietnam Securities Depository and Clearing Corporation (VSDCC)</u>.</p>	
<p>Chapter V: FINANCIAL STATEMENTS, ANNUAL REPORT, AUDITING, RETENTION, INVESTIGATION OF RECORDS AND INFORMATION DISCLOSURE</p>	<p>Chapter V: FINANCIAL STATEMENTS, ANNUAL REPORT, AUDITING, ARCHIVES, INVESTIGATION OF RECORDS AND INFORMATION DISCLOSURE</p>	
<p>Article 58. Annual, semi-annual and quarterly reports</p>	<p>Article 58. Annual, interim and quarterly reports</p>	
<p>2. The above reports and records must be sent to the Board of Directors to assign the Audit Committee to assess at least thirty (30) days before the opening of the annual meeting of the General Meeting of Shareholders.</p>	<p>2. The above reports and records must be sent to the Board of Directors to assign the Audit Committee to assess at least thirty (30) days before the opening of the Annual General Meeting of Shareholders.</p>	<p>Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.</p>

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
3. Reports and records prepared by the Board of Directors and auditing report must be available at the head office of DHG PHARMA at least ten (10) days before the opening of the annual meeting of the General Meeting of Shareholders.	3. Reports and records prepared by the Board of Directors and auditing report must be available at the head office of DHG PHARMA at least ten (10) days before the opening of the annual meeting of the General Meeting of Shareholders. <u>The shareholders that have held the Company's shares for at least 01 years are entitled to examine the reports mentioned in this Article themselves or together with their lawyers, accountants or certified auditors</u>	Adding the content in accordance with clause 4, Article 175 of the Law on Enterprises 2020 and Article 55 of the Model Charter under Circular 116/2020/TT-BTC
Article 61. Retention of records 1. The Board of Directors of DHG PHARMA must retain the following records: f. Report of the Audit Committee, conclusion of inspection agency, conclusion of an independent audit firm;	Article 61. Retention of records 1. The Board of Directors of DHG PHARMA must archive the following records: f. Report of the Audit Committee, conclusion of inspection agency, conclusion of an independent audit firm;	Revising the Vietnamese name of Committees to unify the names of Committees under the Board of Directors.
Article 62. Right to investigate books and records	Article 62. Right to investigate books and records	
	<u>b) The shareholder or group of shareholders that hold at least five percent (05%) of ordinary shares is entitled to review, examine, extract the minutes, resolutions, and decisions of the Board of Directors, interim and annual financial statements, reports of Audit Committee, contracts and transactions subject to approval by the Board of Directors and other documents, except documents relevant to the Company's trade secrets.</u>	Adding the content in accordance with Article 115 of the Law on Enterprises 2020 and point a, clause 1, Article 49 of the Model Charter under Circular 116/2020/TT-BTC
Chapter IX: AMENDMENT AND SUPPLEMENT OF THE CHARTER AND EFFECTIVE DATE	Chapter IX: AMENDMENT AND SUPPLEMENT OF THE CHARTER AND EFFECTIVE DATE	

CURRENT CONTENTS	AMENDED AND SUPPLEMENTED CONTENTS	EXPLANATIONS
<p>Article 77. Effective date 1. This Charter includes nine (09) Chapters, seventy-seven (77) Articles and takes effect on 29 June 2020.</p>	<p>Article 77. Effective date 1. This Charter includes nine (09) Chapters, seventy-seven (77) Articles and takes effect on <u>[dd, mmm, 2021]</u>.</p>	<p>Updating number, date of issuance of the Resolution according to the Annual General Meeting of Shareholders 2020</p>
<p>2. This Charter is made in ten (10) copies of equal validity, of which: a. One (01) copy shall be submitted to the local Public Notary Office. b. Five (05) copies shall be registered with a governmental authority in accordance with the regulations of the People's Committee of Can Tho City. c. Four (04) copies shall be filed in the office of DHG PHARMA.</p>	<p>c. Four (04) copies shall be archived in the <u>headquarters</u> of DHG PHARMA.</p>	<p>The applicable law does not require the submission of: One (01) copy at the local State Notary Office and Five (05) copies at the authority for registration in accordance with the regulations of the People's Committee of Can Tho City. So, this content shall be removed.</p>

GENERAL DIRECTOR

Masashi Nakaura

**Cantho, 2021
MANAGER OF LEGAL DEPARTMENT**

Vo Hoang Tam

[NOTICE: This Convocation Notice is a translation of the Vietnamese language original for convenience purpose only, and in the event of any discrepancy, the Vietnamese language original shall prevail.]